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0.7 mol/L/L; P  0.001) concentrations. Pre-dialysis ET-1Hemodynamic changes during hemodialysis: Role of nitric
levels were significantly higher in ESRD patients compared tooxide and endothelin.
the controls (8.0  1.9 vs. 12.7  4.1 pg/mL; P  0.002), butBackground. Etiology of dialysis induced hypotension and
were comparable in the three study groups. Post-dialysis ET-1hypertension remains speculative. There is mounting evidence
levels did not change significantly in Group I compared to pre-that nitric oxide (NO) and endothelin (ET-1) may play a vital
dialysis values (14.3  4.3 vs.15.0  2.4 pg/mL, P  NS).role in these hemodynamic changes. We examined the intradia-
However, while the ET-1 concentration decreased significantlylytic dynamic changes in NO and ET-1 levels and their role in
in Group II (12.0  4.0 vs. 8.7  1.8 pg/mL, P  0.05), it in-the pathogenesis of hypotension and rebound hypertension
creased in Group III from pre-dialysis levels (12.8  3.8 vs.during hemodialysis (HD).
16.7  4.5 pg/mL, P  0.06).Methods. The serum nitrate nitrite (NT), fractional exhaled
Conclusion. Pre-dialysis FENO is elevated in patients withNO concentration (FENO), l-arginine (L-Arg), NGNG-dimethyl-
dialysis-induced hypotension and may be a more reliable thanl-arginine (ADMA) and endothelin (ET-1) profiles were stud-
NT as a marker for endogenous NO activity in dialysis patients.ied in 27 end-stage renal disease (ESRD) patients on HD and
Altered NO/ET-1 balance may be involved in the pathogenesis6 matched controls. The ESRD patients were grouped accord-
of rebound hypertension and hypotension during dialysis.ing to their hemodynamic profile; Group I patients had stable
BP throughout HD, Group II had dialysis-induced hypoten-
sion, and Group III had intradialytic rebound hypertension.
Results. Pre-dialysis FENO was significantly lower in the dial- Symptomatic hypotension occurs in more than 25%ysis patients compared to controls (19.3  6.3 vs. 28.6  3.4
of hemodialysis (HD) sessions [1], but the etiology of di-ppb, P 0.002). Between the experimental groups, pre-dialysis
alysis-induced hypotension remains speculative. The pro-FENO was significantly higher in Group II (24.1  6.7 ppb)
compared to Group I (17.8  5.6 ppb) and Group III (16.1  posed mechanisms include delayed plasma refilling from
4.2 ppb; P  0.05). Post-dialysis, FENO increased significantly the extravascular space, uremic dysautonomia, activation
from the pre-dialysis values (19.3  6.3 vs. 22.6  7.9 ppb; P  of cytokines, changes in blood osmolality and release of0.001). Pre-dialysis NT (34.4  28.2 mol/L/L) level was not
neurohumoral mediators. In a small number of patients,significantly different from that of controls (30.2  12.3 mol/
dialysis and ultrafiltration are associated with a progres-L/L). Serum NT decreased from 34.4 28.2mol/L/L at initia-
tion of dialysis to 10.0  7.4 mol/L/L at end of dialysis (P  sive and significant increase in blood pressure [2]. The
0.001). NT concentration was comparable in all the three mechanism of this paradoxical hypertension remains
groups at all time points. Pre-dialysis L-Arg (105.3  25.2 speculative, but has been hypothesized to be due to aug-vs. 93.7  6.0 mol/L/L; P  0.05) and ADMA levels were
mented release of renin and activation of sympatheticsignificantly higher in ESRD patients (4.0  1.8 vs. 0.9 
nervous system [3]. Inadequate reflex vasoconstriction0.2 mol/L/L; P  0.001) compared to controls. Dialysis re-
sulted in significant reduction in L-Arg (105.3 25.2 vs. 86.8 in response to hypovolemia may occur during HD, but
19.8 mol/L/L; P  0.005) and ADMA (4.0  1.8 vs. 1.6  not during isolated ultrafiltration (UF) [1], suggesting
that either some vasoconstrictor material is removed or
vasodilator is generated during dialysis [4].Key words: dialysis, hypotension, hypertension, cytokines, asymmetric
dimethyl arginine, l-arginine, fractional exhaled nitric oxide. Emerging evidence indicates that endothelial dysfunc-
tion may play a key role in hemodynamic instabilityReceived for publication June 27, 2001
during hemodialysis. In response to mechanical andand in revised form September 5, 2001
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endothelial derived relaxing factor, nitric oxide (NO), III). Patients with pulmonary diseases, ongoing infection
or inflammatory diseases and diabetes were excludedand the vasoconstrictive factor, endothelin (ET-1). NO is
a labile agent that is synthesized from terminal guanidine from the study. Also, patients with poor left ventricular
function and ischemic heart disease requiring nitratesnitrogen atoms of the amino acid l-arginine (L-Arg) by a
family of enzymes, NO synthases (NOS). In vitro studies for coronary vasodilatation or angiotensin converting
enzyme inhibitor were not recruited because these couldhave suggested that the activity of NO synthase is in-
creased when blood is exposed to hemodialysis mem- potentially effect the results [12]. Diet was unrestricted,
with the patients allowed to eat and drink as usual. Mark-brane materials [5]. Although disputed [6], preliminary
evidence indicates that NO may mediate dialysis induced ers of NO synthesis, ADMA, L-Arg and ET-1 levels
were measured in six matched controls for comparison.hypotension [7]. ET-1 is a 21-residue vasoconstrictor
peptide that acts in a paracrine manner on the vascular
Methodssmooth muscle and continuously regulates peripheral
vascular resistance. Thus, ET-1 may modulate the vascu- All the patients were dialyzed with polysulfone (Hemo-
flow, F80; Fresenius AG, Walnut Creek, CA, USA) dia-lar reaction and determine the hemodynamic response
to intravascular volume changes during hemodialysis. lyzer for four hours. Blood and dialysate flow rates were
318  123 mL/min and 720  210 mL/min. DialysateOne possible explanation for the development of hy-
pertension or hypotension in some HD patients is that NO composition was as follows: sodium (Na) 139 mEq/dL,
bicarbonate (HCO3) 35 mEq/dL, calcium (Ca) 3.5and ET-1 might show inter-individual variation in res-
ponse to dialysis and intradialytic hemodynamic changes. mEq/L, magnesium (Mg) 1 mEq/L and dextrose 200
mg/dL. During hemodialysis all the patients were anti-Uremic milieu has been reported to favor and to inhibit
NO synthesis [8]. While activation of cytokines during coagulated with unfractionated heparin using a standard
regimen, a 2000 unit initial bolus followed by infusionHD may increase the production of NO [5], it can be
decreased due to diminished NO synthase activity [9], of 1000 U/h. Sodium modeling and cool dialysate were
not used during the treatments. Temperature, pulse andaccumulation of NGNG-dimethyl-l-arginine (asymmetric
dimethylarginine; ADMA) [10] or a decreased bioavail- blood pressure were monitored every 30 minutes. Blood
samples and exhaled air [13] were collected simultane-ability of L-Arg [11]. Hence, NO level should be evalu-
ated in association with its modulators, L-Arg, ADMA, ously at the beginning of dialysis, middle and end of
dialysis. Dialysate samples were also collected at theand ET-1. While the pathogenesis of dialysis-induced
hypotension remains controversial, the role of these va- same time frequency.
All the patients underwent echocardiography on thesoactive substances in dialysis induced rebound hyper-
tension remains unexplored. We studied NO (by stable day after dialysis either prior or after the study. Ejection
fraction was used as an index of systolic function. Leftproducts of NO metabolism nitrate/nitrite and fractional
exhaled NO concentration, FENO), ET-1, ADMA and ventricular mass was calculated as described by Deve-
reux and Reicheck [14]. Adequacy of dialysis was com-L-Arg levels in three groups of patients: (a) patients with
stable intradialytic hemodynamics, (b) dialysis induced puted by the Dauguirdas second generation formula [15].
Basic laboratory information also was obtained.hypotension, and (c) dialysis-induced hypertension.
Fractional exhaled nitric oxide measurement
METHODS
Exhaled nitric oxide was collected and measured as
Subjects previously described [13]. In short, the subject was asked
to perform a slow vital capacity maneuver exhaling atPatients were selected from a pool of 124 end-stage
renal disease (ESRD) patients on HD. The protocol was 100 mL/sec into a Tedlar bag. The NO concentration in
the bag was analyzed within 24 hours [13], using a NOapproved by the Human Research Review Committee
at the Louisiana State Medical University. Informed chemiluminescence analyzer (Model 270B; Sievers, Boul-
der, CO, USA). Dead space air was not discarded be-written consent was obtained from all the patients and
volunteers. Dialysis records of patients on HD were re- cause ambient NO was 20 ppb.
viewed to identify those who manifested the following
Nitrate and nitrite measurementsfeatures during at least one dialysis every week during
the previous three months of treatments. Patients di- Nitrite and nitrate (NT) were measured in the serum
using the Griess reaction [16]. The amount of nitrite wasvided into those with stable blood pressure throughout
the HD (Group I), those who had decrease in mean calculated by comparison to a standard curve of sodium
nitrite with sensitivity of the assay of approximatelyarterial pressure (MAP)15 mm Hg from baseline dur-
ing HD (Group II), and those who were normotensive 1 mol/L. Nitrite  nitrate was measured by reducing
nitrate to nitrite using aspergillus nitrate reductase (finalor hypertensive at initiation of dialysis, but experienced
elevation in MAP of 15 mm Hg intradialysis (Group concentration 0.1 U/mL; Boehringer Mannheim, India-
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napolis, IN, USA) in the presence of nicotinamide ade- Cytokine assay
nine dinucleotide phosphate (NADPH; final concen- Tumor necrosis factor  (TNF) and interleukin-1
tration 0.086 mmol/L), KH2PO4 (final concentration (IL-1) were measured in the serum because of their
0.062 mol/L), and flavin adenine dinucleotide (FAD; fi- capacity to induce NOS expression using commercially
nal concentration 0.011 mmol/L) for 60 minutes at room available enzyme-linked immunosorbent assay (ELISA)
temperature [16]. The nitrate  nitrite was then mea- kits (R&D Systems, Minneapolis, MN, USA) according
sured as nitrite using the above techniques. Nitrate was to the manufacturer’s directions. The sensitivity of these
calculated by subtracting nitrite from nitrite  nitrate. assays was 15 pg/mL for TNF and 3.9 pg/mL for IL-1.
To measure the amounts of nitrite and nitrate in the
Statisticsdialysate, the Griess reaction was inadequate due to poor
Statistical analysis was done by Minitab (Minitab, Re-sensitivity. Therefore, we used a modification of the
lease 11, USA). The data are expressed as mean and stan-method described by Archer for the measurement of
dard deviation. The Student t test and analysis of variancelow amounts of nitrite [17]. In brief, nitrite was converted
(ANOVA) were used wherever applicable. Tukey’s testto NO under acidic conditions in the presence of a halide
was used to test the significance of the difference be-under a nitrogen stream, which was then diverted
tween groups and Dunnets’ test was used to estimateinto a NO analyzer. The amount of nitrite was calculated
the significance of the change over time. Simple linearby comparison to a standard curve of sodium nitrite with
regression analysis was used to assess the correlation.sensitivity of the assay 20 nmol/L. Nitrite nitrate was
measured by reducing nitrate to nitrite using Aspergillus
nitrate reductase as above. The nitrate nitrite (NT) was RESULTS
then measured as nitrite using the above techniques [16]. Demographics and hemodynamic profile
Three patients and four observations were excludedL-Arginine and ADMA assay
from the study because of unexpected change in hemody-
Quantification of serum L-Arg and ADMA were per- namics on the day of the experiments. The mean age of
formed on a Beckman Model 6300 Amino Acid Analyzer the patients was 57.1  2.0 years. There were 13 males
(Beckman Instruments Inc., Palo Alto, CA, USA). Se- and 14 females. Etiology of ESRD was hypertension in
rum samples were processed by deproteinization, and the 11, glomerulonephritis in 4, tubulointerstitial disease in 3,
protein-cleared supernatant fluids subsequently stored at adult polycystic kidney disease in 2, and unknown in 7.
	20
C until analyzed. Separation of plasma amino acids Duration of dialysis was 3.8 0.3 hours. Age, dry weight,
was performed on a 10 cm Pickering 100 mm  4.6 hemoglobin and albumin level of the patients in Group
ID cation ion-exchange resin column. Following heat II was significantly lower compared to Group I (Table
development with ninhydrin, amino acids were quanti- 1). Although ejection fraction was comparable, the left
fied by absorbance analysis at 570 nm for area-to-area ventricular mass index (LVMI) was significantly higher
in Group II compared to Group I (P  0.04). Systolic,comparison with known standards.
diastolic and mean arterial pressures (MAP) were sig-
Endothelin assay nificantly lower in Group II compared to Group I and
Group III. Figure 1 shows the intradialytic change inBlood samples were obtained with pre-chilled syringes.
MAP in the study groups. In Group II, MAP declinedThe samples were transferred to ice-cold polypropylene
from baseline 95.2  20.1 mm Hg to 75.9  13.2 mm Hgtunes containing 1 mg/mL of K2-ethylenediaminetetra-
at the third hour of dialysis and remained stable hence-acetic acid (K2-EDTA; Sigma Chemicals Co, St. Louis,
forth at a lower level throughout dialysis (P  0.03). InMO, USA) and 500 KIU/mL aprotinin (Boehringer
response to hypotension, ultrafiltration was slowed downMannheim, Mannheim, Germany). Plasma was sepa-
in six patients, and four patients required intravenous
rated by centrifugation at 3000 RPM for 15 minutes at
normal saline to maintain the BP values. In contrast,
4
C and stored at 	70
C until assayed. Plasma ET-1 MAP increased significantly from the initial value of
was extracted through Sep-Pak C18 Cartridge (Waters 116.7  9.0 to 128.5  13.4 mm Hg in Group III during
Associates, Milford, MA, USA). ET-1 was measured dialysis (P 0.04). Two patients were treated with cloni-
using a radioimmunoassay kit (Peninsula Lab, Inc., Bel- dine to control blood pressure. Pulse rate increased ap-
mont, CA, USA). The recovery capability and the speci- propriately and significantly in response to hypotension
ficity for ET-1 using this assay were 85% and 100%, in Group II.
respectively. The lowest level of detection was 1 pg/mL
Change in FENO and NT during dialysisand the 50% intercept was 30 pg/tube. The intra-assay
and interassay coefficient of variations were 7% and 9%, Pre-dialysis (all; 19.3 6.3 ppb) FENO was significantly
lower in dialysis patients compared to controls (28.6 respectively.
Raj et al: Endothelin, NO and BP700
Table 1. Demography and blood pressure profile of the study population
Group 1 Group 2 Group 3
N9 N9 N9 P
Age years 50.913.3 63.18.3a 57.113.4 0.03
Weight kg 87.115.8 63.69.4a 77.312.7 0.002
Ejection fraction % 52.76.9 48.97.8 50.49.1 NS
LVMI g/m2 129.146.3 171.342.1a 14137.6 0.04
Hemoglobin g 11.30.3 9.90.5 10.61.7 0.05
EPO/week 124297231 162866211 128578255 NS
Albumin g/dL 3.90.6 3.40.5a 3.90.3 0.05
Ultrafiltration L 3.81.4 3.71.0 3.41.1 NS
Systolic BP 130.520.4 119.231.0 175.226.6a 0.001
Diastolic BP 75.98.6 64.317.0 97.619.0a 0.001
MAP 94.110.1 82.619.6 123.516.4a 0.001
 MAP from baseline 	0.45.5 	18.722.5a 10.917.4a 0.004
Pulse rate/min 75.520.2 88.218.3a 82.924.6 0.01
Abbreviations are: LVMI, left ventricular mass index; EPO, erythropoietin; BP, blood pressure; MAP, mean arterial BP; , change.
a P  0.05
0.2 mol/L/L, P 0.001) levels were significantly higher
in ESRD patients compared to the controls. Dialysis
resulted in significant reduction in L-Arg concentration
(105.3  25.2 vs. 86.8  19.8 mol/L/L, P  0.005).
Although ADMA levels also declined significantly post-
HD (4.0  1.8 vs. 1.6  0.7 mol/L/L, P  0.001), they
were still significantly higher than the ADMA concentra-
tion in controls (P  0.001). The ratio of L-Arg/ADMA
increased significantly post-HD compared to pre-dialysis
values (33.9  21.3 vs. 72.6  45.5, P  0.001), but was
still lower than the ratio observed in controls (72.6 Fig. 1. Mean arterial blood pressure (MAP) during hemodialysis. MAP
45.5 vs. 105.8  16.0, P 0.01). There was no differenceremained stable in group I (; N  9), decreased in group II (; N 
9, P  0.03), but increased in group III (; N  9, P  0.04). in the L-Arg and ADMA levels or L-Arg/ADMA ratio
between the three study groups. L-Arg or ADMA levels
did not correlate with plasma NT or FENO levels.
3.4 ppb; P  0.002). Between the experimental groups,
Plasma ET-1 profilepre-dialysis FENO was significantly higher in Group II
Pre-dialysis (all) ET-1 levels were significantly highercompared to others (Table 2). Post-dialysis (all), FENO in-
in dialysis patients compared to the controls (12.7  4.1creased significantly from the pre-dialysis values (19.3
vs. 8.0  1.9 pg/mL, P  0.002), but were comparable6.3 vs. 22.6  7.9 ppb, P  0.001). On the other hand,
in the three study groups. The post-dialysis ET-1 levelthe pre-dialysis (34.4  28.2 mol/L/L) NT level was
did not change significantly in Group I compared to pre-not significantly different from that of controls (30.2 
dialysis values (14.3 4.3 vs. 15.0 2.4 pg/mL, PNS).12.3mol/L/L). Concentration of NT in the effluent dial-
ysate increased significantly from 9.4  3.3 mol/L/L at While the ET-1 concentration decreased significantly in
initiation to 29.1  5.7 mol/L/L at mid-dialysis, and Group II (12.0  4.0 vs. 8.7  1.8 pg/mL, P  0.05), it
subsequently declined to 14.1 3.3 mol/L/L at the end increased in Group III from pre-dialysis levels (12.8 
of dialysis (P  0.001; Fig. 2). Dialysate loss of NT was 3.8 vs.16.7  4.5 pg/mL, P  0.06; Fig. 3). Post-dialysis
associated with a progressive decrease in serum NT from ET-1 was significantly lower in Group II compared to
34.4  28.2 mol/L/L at initiation of dialysis to 10.0  Group I and Group III (P  0.001). Cytokines TNF-
7.4 mol/L/L at end of dialysis (P  0.001). NT concen- and interleukin-1 (IL-1) did not change significantly
tration was comparable in all the three groups at all time during the dialysis and was comparable between the
points. Pre-dialysis NT and FENO demonstrated only a three groups (Fig. 4).
modest correlation with MAP, systolic and diastolic
blood pressure (P  NS, all comparisons).
DISCUSSION
Pre- and post-dialysis L-Arg and ADMA Nitric oxide and ET-1 contribute to the complex regu-
lation of local and systemic vascular resistance, distribu-Pre-dialysis (all) L-Arg (105.3  25.2 vs. 93.7 
6.0 mol/L/L, P 0.05) and ADMA (4.0  1.8 vs. 0.9  tion of blood flow and oxygen delivery, sodium balance
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Table 2. Fractional exhaled nitric oxide (NO) concentration (FENO), plasma: Nitrate (nitrate  nitrite), l-arginine and
asymmetric dimethyl arginine (ADMA) concentration during dialysis
Control Group 1 Group 2 Group 3
FENO ppb 28.63.4b
Pre-dialysis 17.85.6 24.16.7a 16.14.2
Mid-dialysis 18.94.5 21.19.5 18.05.1
Post-dialysis 19.93.8 23.17.4 21.76.8
Nitrate lmol 30.212.3
Pre-dialysis 40.912.4d 40.19.4d 32.720.0d
Mid-dialysis 19.69.7 11.15.6 12.69.1
Post-dialysis 13.12.2 9.72.0 7.27.1
l-Arginine lmol/L 93.76.0
Pre-dialysis 101.822.1 101.513.5e 112.435.7
Post-dialysis 84.515.9 86.09.7 89.730.3
ADMA lmol/L 0.90.2c
Pre-dialysis 3.51.4e 4.01.3e 4.52.5e
Post-dialysis 1.40.8 1.70.7 1.50.7
L-Arg/ADMA 105.816.0c
Pre-dialysis 36.320.9f 29.214.4f 36.228.2f
Post-dialysis 81.958.7 60.731.0 75.445.6
a Comparison between groups (P  0.05)
b Control vs. pre-dialysis values in groups I and III (P  0.002)
c Control vs. pre-dialysis values in each group (P  0.001)
d Pre-dialysis value vs. mid and post-dialysis values (P  0.001)
e Pre-dialysis vs. post-dialysis value (P  0.01)
f Pre-dialysis vs. post-dialysis value (P  0.04)
Fig. 2. Serum () and dialysate () concentrations of nitrite  nitrite
(NT) during hemodialysis (N 27, mean SD). Dialysate NT increased
significantly from base line at mid-dialysis (*P  0.001) and then de-
creased. Serum NT concentration decreased significantly from pre-dial-
ysis values at mid and post-dialysis (*P  0.001).
Fig. 3. Plasma endothelin (ET-1) levels remained unchanged in group
I (N  9), decreased in group II (N  9, P  0.001), but increased in
group III during hemodialysis (N  9, P  0.001). Pre-HD ET-1 levelsand arterial pressure [18, 19]. Excessive NO can result
in groups I, II and III were 14.3 4.2, 12.0 4.0 and 12.8  3.8 pg/mL,in systemic hypotension as in septic shock; conversely, respectively. Post-HD ET-1 levels in groups I, II and III were 14.8 
impaired NO synthesis may lead to pathologic vasocon- 2.6, 7.9  2.1 and 16.8  4.5 pg/mL, respectively (P  0.001).
striction, tissue ischemia with organ dysfunction, and to
the genesis or perpetuation of hypertension [18]. We
found that the pre-dialysis FENO was elevated in patients in patients with rebound hypertension, decreased in pa-
prone for intra-dialytic hypotension, but serum NT, tients with dialysis induced hypotension, but remained
L-Arg and ADMA levels were not significantly different unchanged in the hemodynamically stable group. These
in patients with and without hypotension. Concentra- observations indicate that the NO/ET-1 balance may play
tions of NT, ADMA and L-Arg decreased post-dialysis, a key role in dialysis related hemodynamic changes. The
but FENO increased compared to pre-dialysis values in all incidence and magnitude of hypotension during HD var-
the patients. However, the intradialytic change in ET-1 ies from patient to patient, even when the ultrafiltration
levels did not follow a uniform pattern. Compared to the rate is the same. While the absolute amounts of fluid re-
moved was comparable in the three groups of patients,pre-dialysis value, the post-dialysis ET-1 level increased
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dynamic effect of L-Arg is due to the formation NO from
L-Arg [25]. Mehta, Stewart and Levy demonstrated a
significant correlation between hypotensive response to
L-Arg infusion and increase in FENO [25]. Despite nu-
merous reports, the site of production of FENO remains
speculative. Preliminary evidence suggests that the source
may be bronchial epithelial cells, alveolar cells and pul-
monary vasculature [26]. FENO may not only represent
the local production of NO in the airway, but also its
systemic activity in various physiological and pathologi-
Fig. 4. Serum tumor necrosis factor  (TNF; ) and interleukin-1 cal conditions. Madore et al [27] and Sumino et al [6]
(IL-1; ) levels did not change during hemodialysis (N  27, mean 
reported that post-dialysis FENO was significantly lowerSD, P  NS).
than the pre-dialysis FENO. However, we found that the
post-dialysis FENO was significantly higher compared to
the pre-dialysis measurements, which may be related to
when corrected for the body weight the UF may be relief of hypoxia [28] by ultrafiltration during HD.
relatively higher in the hypotensive group. We also inves- Plasma L-Arg is reported to be unchanged, increased
tigated possible cardiac cause for the hypotensive epi- [29] or decreased [30] in ESRD patients. In our patients,
sodes. Although the systolic function as estimated by the the pre-dialysis L-Arg level was higher than the concen-
ejection fraction was comparable, the LVMI was higher tration in controls. We also found that both pre- and
in patients with hypotension, indicating subtle cardiac post dialysis ADMA level were significantly higher than
dysfunction and insufficient cardiac reserve. the control values. MacAllister, Whitley and Vallance
In vivo activity of NO is difficult to monitor because showed that ADMA inhibits the NO synthesis and endo-
it is very unstable. Since nitrite is rapidly converted to thelium dependent relaxation of blood vessels at concen-
nitrate in the serum, the nitrite levels were not unexpect- trations of a similar order to that occur in plasma of
edly below the level of detection in our study. Endotoxin patients with ESRD [31]. Decreased L-Arg levels may
transfer across the membrane and blood-membrane in- become the major limiting factor in NO production, es-
teraction could result in activation of cytokines, such as pecially in conditions of increased ADMA/L-Arg ratio
TNF- and IL-1, which in turn induces inducible NOS [31]. We did not find the ratio of L-Arg/ADMA to be
(iNOS). Transcription of mRNA encoding for the iNOS different in the three study groups. The L-Arg/ADMA
takes at least two hours, and the following protein syn- ratio increased post-dialysis, which may favor NO syn-
thesis requires more time [20]. Therefore, increased NO thesis. This is supported by the observation by Noris et
production may not be detectable until after dialysis. al, who showed that post-dialysis plasma human induced
However, regular HD exposes patients to periodic stimu- more NO synthesis from umbilical cells compared to
lation of NO synthesis leading to higher baseline NO pre-dialysis plasma [32].
levels. Nishimura et al [21] and Lin et al [22] showed that There are discordant data about the impact of hemodi-
patients with hypotension have increased pre-dialysis NT alysis on ET-1 levels as it has been reported to be un-
levels. However, an increase in pre-dialysis NT should changed [33], increased [34] or decreased [35] post-dial-
not be automatically interpreted as increased synthesis, ysis. ET-1 levels may vary with the type of membrane
because it could be due to decreased clearance during used during HD and UF rate [36]. Akizawa, Kinugasa
the interdialytic period resulting in progressive accumu- and Koshikawa [37] and Shichiri et al [38] found a higher
lation. Yokokawa et al observed that the pre-dialysis concentration of ET-1 in hemodialyzed hypertensive pa-
NT was comparable in patients with hypotension and tients compared to normotensive subjects. On the other
hypertension, but it increased significantly post-HD only hand, Stockenhuber et al [39] and Niwa et al [40] re-
in patients with hypotension [7]. In our study, the depura- ported that the plasma ET-1 levels were similar in ESRD
tion of NT during dialysis resulted in a progressive de- patients with and without hypertension. We found that
cline in NT concentration. There was no significant dif- the pre-dialysis ET-1 levels were comparable among the
ference in the NT levels at any point of time during HD three groups, but significantly higher than the controls.
in the three study groups. We believe that not only is However, ET-1 levels decreased in patients with hypo-
NT is an indirect measurement of NO release, it is re- tension, but increased in patients with hypertension, sug-
moved by dialysis rendering it an unreliable marker of gesting a cause and effect relationship.
NO generation. The relationship between NO and other vasoconstric-
Parental administration of L-Arg reverses the acute tor systems is variable [41]. At physiologic levels, ET-1
hypertensive effect of NOS inhibition in animals [23], and unexpectedly is a vasodilator, possibly via NO generation
[41]. On the other hand, when vasoconstrictor activityhas acute hypotensive effect in humans [24]. The hemo-
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7. Yokokawa K, Mankus R, Saklayen MG, et al: Increased nitricis high, NO is very important in maintenance of renal per-
oxide production in patients with hypotension during hemodialysis.
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